Non-Hodgkin’s Lymphoma (NHL) Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Non-Hodgkin’s Lymphoma Information Center has current, evidence-based information for you. Get the facts about non-Hodgkin’s lymphoma early detection, treatment, and survivorship, and stay up to date with ongoing non-Hodgkin’s lymphoma research that could impact your treatment decisions through our daily cancer news.
Headline NHL News 
Following Lifestyle Recommendations Reduces Risk of Cancer Death
People who follow the diet and lifestyle recommendations laid out by the WCRF and the AICR have a 20 percent reduced risk of dying from cancer.
RIT Conditioning with Zevalin Prior to Autologous Transplantation Improves Overall Survival in Patients with DLCL
RIT conditioning with Zevalin improves overall survival in patients with diffuse large cell lymphoma.
Treanda Plus Rituxan is Not Inferior to R-CHOP and R-CVP for advanced NHL
Treanda plus Rituxan is noninferior to the commonly used regimens R-CHOP and R-CVP in treating advanced NHL.
Non-Hodgkin's Lymphoma Tips
What is Radioimmunotherapy (RIT) Treatment of NHL? Radioimmunotherapy (RIT) is a type of targeted therapy that delivers radiation directly...
Advanced Directives Living Wills Every competent adult has, in most cases, the freedom to accept or refuse...
Caregivers What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Non-Hodgkin’s Lymphoma Management
Inspiration, Hope & Resources
On Top of the World: Climbing Everest & Beating Cancer Twice Sean Swarner is a master of setting a goal and achieving it. So when he...
Jack & Jill Late Stage Cancer Foundation Jon Albert, founder of the Jack & Jill Late Stage Cancer Foundation shows the...
Moving Bodies, Changing Lives Moving On Aerobics helps women regain joy of movement and physical fitness after...
Non-Hodgkin’s Lymphoma Clinical Trials
COGANHL01P1 – A Pilot study to determine the Toxicity of the addition of Rituximab to the Inducation and Consolidation phases and the Addition of Rasburicase to the Reduction Phase in Children with Newly Diagnosed Advanced B-cell leukemia/lymphoma treated with LMB/FAB Therapy
SeaGenMarinerStudy – A Randomized Phase IIb Placebo-controlled study of R-ICE Chemotherapy (RItuximab, Ifosfamide, Carboplatin, and Etoposide) with and without SGN-40 (anti-CD40 humanized monoclonal antibody) for second-line treatment of patients with diffuse large B-cell lymphoma (DLBCL)
114-NH-301 – Phase III, Randomized, Double-blind Study of Glaiximab in combination with Rituximab compared with Rituximab in Combination with Placebo for the Treatment of Subjects with Relapsed or Refractory, Follicular Non-Hodgkin’s Lymphoma.
 |
 |
 |
 |
